Eczema Drug's skin secrets probed in small study
NCT ID NCT05378698
First seen Feb 06, 2026 · Last updated Jun 08, 2026 · Updated 16 times
Summary
This study aimed to understand how tralokinumab, a drug for moderate-to-severe eczema (atopic dermatitis), works in the skin. Researchers planned to measure drug levels in skin samples from 24 adults before and after 16 weeks of treatment. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allergy Unit, Dept. of Dermatology, Unviersity Hosptial of Zurich
Zurich, Canton of Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.